Novartis AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance
Phase 4
Completed
- Conditions
- Renal Transplantation
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-01-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 728
- Registration Number
- NCT00150020
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)
Phase 2
Completed
- Conditions
- Symptomatic Gastroespohageal Reflux Disease
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2010-09-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 832
- Registration Number
- NCT00149851
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A302
Phase 3
Completed
- Conditions
- Renal Transplant
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 264
- Registration Number
- NCT00149864
52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine
Phase 3
Completed
- Conditions
- Osteoarthritis
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 3036
- Registration Number
- NCT00145301
- Locations
- 🇩🇪
Novartis, Nuernberg, Germany
To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women
Phase 3
Completed
- Conditions
- Osteopenia
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 455
- Registration Number
- NCT00145275
Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 2456
- Registration Number
- NCT00145327
- Locations
- 🇺🇸
Southern Arizona VA, Tucson, Arizona, United States
🇺🇸University of Arkansas for Medical Science, Little Rock, Arkansas, United States
🇺🇸Osteoporosis Medical Center, Beverly Hills, California, United States
Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States
Phase 4
Completed
- Conditions
- Parkinson's Disease
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 184
- Registration Number
- NCT00143026
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
🇦🇺Watkins Medical Center, Brisbane, Australia
🇦🇺Central Coast Neuroscience Research, Gosford, Australia
Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy
Phase 2
Terminated
- Conditions
- Diabetic Gastropathy
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- Novartis
- Target Recruit Count
- 120
- Registration Number
- NCT00142974
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS
Phase 4
Completed
- Conditions
- IBS-C and IBS With Mixed Bowel Habits
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-01-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 664
- Registration Number
- NCT00142987
Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.
Phase 3
Completed
- Conditions
- Chronic Constipation
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2008-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1026
- Registration Number
- NCT00141089